Literature DB >> 12963997

Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells.

Young-Ae Kim1, Won Ho Lee, Tae Hyun Choi, Sook-Hee Rhee, Kun-Young Park, Yung Hyun Choi.   

Abstract

Resveratrol, a polyphenolic phytoalexin found in grapes, may have the potential for prevention and therapy for human cancer. We report here that resveratrol inhibits the growth of human lung carcinoma A549 cells and provides molecular understanding of this effect. Resveratrol treatment of A549 cells resulted in a concentration-dependent induction of S phase arrest in cell cycle progression. This anti-proliferative effect of resveratrol was associated with a marked inhibition of the phosphorylation of the retinoblastoma protein (pRB) and concomitant induction of cyclin-dependent kinase (Cdk) inhibitor p21WAF1/CIP, which appears to be transcriptionally upregulated and is p53- dependent. In addition, resveratrol treatment resulted in induction of apoptosis as determined by fluorescence microscopy and flow cytometric analysis. These effects were found to correlate with an activation of caspase-3 and a shift in Bax/Bcl-xL ratio more towards apoptosis. Resveratrol treatment also inhibited the transcriptional activity of nuclear transcription factor kappaB (NF-kappaB). Taken together, these findings suggest that resveratrol has strong potential for development as an agent for prevention against human lung cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12963997

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  32 in total

1.  The biology of aging and frailty.

Authors:  Neal S Fedarko
Journal:  Clin Geriatr Med       Date:  2011-02       Impact factor: 3.076

Review 2.  Wine, spirits and the lung: good, bad or indifferent?

Authors:  Stephan L Kamholz
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

Review 3.  Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling.

Authors:  Robert Vander Broek; Grace E Snow; Zhong Chen; Carter Van Waes
Journal:  Oral Oncol       Date:  2013-10-28       Impact factor: 5.337

4.  Resveratrol alters microRNA expression profiles in A549 human non-small cell lung cancer cells.

Authors:  Seunghee Bae; Eun-Mee Lee; Hwa Jun Cha; Karam Kim; Yeongmin Yoon; Hyunjin Lee; Jongran Kim; Yu-Jeong Kim; Hong Ghi Lee; Hoi-Kyung Jeung; Yoo Hong Min; Sungkwan An
Journal:  Mol Cells       Date:  2011-08-29       Impact factor: 5.034

5.  A metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death.

Authors:  Michael R Freeman; Jayoung Kim; Michael P Lisanti; Dolores Di Vizio
Journal:  Cancer Biol Ther       Date:  2011-12-01       Impact factor: 4.742

Review 6.  Resveratrol mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for chemoprevention of cancer.

Authors:  S M Hadi; M F Ullah; A S Azmi; A Ahmad; U Shamim; H Zubair; H Y Khan
Journal:  Pharm Res       Date:  2010-01-30       Impact factor: 4.200

7.  Resveratrol and siRNA in combination reduces Hsp27 expression and induces caspase-3 activity in human glioblastoma cells.

Authors:  Evren Önay Uçar; Aslıhan Şengelen
Journal:  Cell Stress Chaperones       Date:  2019-05-09       Impact factor: 3.667

8.  Time- and concentration-dependent effects of resveratrol in HL-60 and HepG2 cells.

Authors:  U Stervbo; O Vang; C Bonnesen
Journal:  Cell Prolif       Date:  2006-12       Impact factor: 6.831

9.  trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways.

Authors:  G Filomeni; I Graziani; G Rotilio; M R Ciriolo
Journal:  Genes Nutr       Date:  2007-10-18       Impact factor: 5.523

10.  4'-Chloro-3,5-dihydroxystilbene, a resveratrol derivative, induces lung cancer cell death.

Authors:  Jin-yi Wu; Kun-wei Tsai; Jia-jen Shee; Yi-zhen Li; Ching-hsein Chen; Jing-jing Chuang; Yi-wen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.